Mobia Medical (NASDAQ:MOBI) Earns Buy Rating from Analysts at BTIG Research

Equities research analysts at BTIG Research started coverage on shares of Mobia Medical (NASDAQ:MOBI) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $19.00 price target on the stock. BTIG Research’s target price points to a potential upside of 40.74% from the company’s previous close.

Other research analysts have also recently issued reports about the company. Wall Street Zen upgraded Mobia Medical to a “hold” rating in a research note on Saturday, May 16th. The Goldman Sachs Group assumed coverage on Mobia Medical in a research note on Tuesday. They issued a “buy” rating and a $31.00 price objective for the company. Finally, Bank of America assumed coverage on Mobia Medical in a research report on Tuesday. They set a “buy” rating and a $16.00 price target for the company. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $22.00.

Mobia Medical Price Performance

Shares of NASDAQ MOBI opened at $13.50 on Tuesday. The stock has a market capitalization of $446.65 million, a price-to-earnings ratio of 66.00 and a beta of 2.84. Mobia Medical has a fifty-two week low of $10.19 and a fifty-two week high of $14.04.

Insiders Place Their Bets

In other Mobia Medical news, Director Cynthia L. Lucchese acquired 125,000 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $1,875,000.00. Following the completion of the transaction, the director directly owned 125,000 shares of the company’s stock, valued at $1,875,000. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William T. Harrington acquired 533,333 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $15.00 per share, with a total value of $7,999,995.00. Following the completion of the transaction, the director directly owned 2,006,716 shares of the company’s stock, valued at approximately $30,100,740. This represents a 36.20% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders bought 1,268,332 shares of company stock valued at $19,024,980.